Clinical Research Administration Fundamentals
This section serves as an entry point into clinical research administration for readers who need grounding in the field before working through its more specialized sub-topics. Clinical research administration sits at the intersection of medicine, regulatory law, data science, and institutional operations, and its practitioners are expected to understand how a trial moves from an initial research question through regulatory authorization, conduct, data collection, safety monitoring, and eventual reporting or submission. The broader field is shaped by the same reference points that recur throughout this cluster: the ICH (International Council for Harmonisation) guideline series, which spans everything from general trial design principles to safety reporting and quality standards for investigational products; national regulatory authorities such as the FDA and EMA, which authorize and inspect trial conduct; and professional and standards bodies such as SCDM, CDISC, and the ACRP/SOCRA certification framework, which govern data practices and workforce competency respectively. A newcomer encountering clinical research administration for the first time will run into all of these bodies in some form, which is why this fundamentals page exists as a map rather than a substitute for the more specific pages that follow. Topics covered here include the basic vocabulary of trial phases and roles, the lifecycle of a trial from protocol development to closeout, the general regulatory and ethical principles (such as informed consent and human subjects protection) that apply across virtually every trial, and an orientation to how the more specialized areas in this cluster - regulatory submissions, IMP manufacturing, data management, biostatistics, safety, and workforce credentialing - relate to one another as a trial progresses from planning to completion.
Guides
No-Show and Missed-Visit Billing Policy for Clinical Trial Participants: What Sponsors and Sites Can (and Can’t) Charge
A missed clinical trial visit raises three separate billing questions — claim billing to Medicare, a direct no-show fee to the participant, and sponsor cost responsibility under the CTA budget. This guide separates the three and covers what’s actually permissible in each.
Clinical Trial Charge Capture and Billing Reconciliation: Closing the Gap Between Coverage Analysis and Claims
How research billing offices confirm that a finished coverage-analysis billing grid actually reaches the claim correctly: charge routing, claims-editing markers, reconciliation cadence, and where double billing and missed revenue actually happen downstream of coverage analysis.
OIG Self-Disclosure Protocol for Clinical Research Billing Overpayments: When and How to Use It
When a clinical research billing overpayment is entangled with possible Anti-Kickback Statute exposure, HHS-OIG’s Health Care Fraud Self-Disclosure Protocol offers a reduced damages multiplier, lower minimum settlement amounts, and a presumption against a Corporate Integrity Agreement — but only for genuinely voluntary disclosures, and only for conduct within its scope.
Medicaid Coverage of Clinical Trial Routine Costs: The Clinical Treatment Act Explained
How the Clinical Treatment Act made routine-cost coverage for clinical trial participants a mandatory Medicaid benefit nationwide, and how it differs from Medicare NCD 310.1 and TRICARE coverage.
TRICARE Clinical Trial Coverage: DOD’s Final Rule and What Changed for Military Beneficiaries
DOD’s 2025 final rule (32 CFR 199) makes TRICARE’s clinical-trial routine-cost benefit permanent and general to NIH-sponsored Phase I-IV trials for severe, life-threatening, or rare conditions — replacing the earlier COVID-19-only provision. Here’s what changed and how it differs from Medicare’s NCD 310.1.
Stark Law and Clinical Research: How the Physician Self-Referral Exception Applies to Investigators
Stark Law’s physician self-referral rules reach clinical trial investigator compensation whenever a physician-investigator is paid by an entity that also furnishes Medicare-covered services. This guide covers what Stark prohibits, the compensation exceptions institutions actually use for investigator agreements, and how Stark differs from the Anti-Kickback Statute.
Hub-and-Spoke Clinical Trial Site Networks: Structure, Benefits, and Operational Considerations
A structural guide to hub-and-spoke clinical trial site networks: how the hub-spoke model is organized, why sponsors adopt it, key operational considerations (staffing, data consistency, monitoring, IRB oversight), and how it compares to fully decentralized trial designs.
Coverage with Evidence Development (CED): CMS’s Medicare Coverage Mechanism
How CMS’s Coverage with Evidence Development (CED) mechanism conditions Medicare payment on registry or clinical-study participation, and what it means for research administration and billing.
Category A vs. Category B IDE Studies: Medicare Coverage Differences
FDA assigns every Investigational Device Exemption (IDE) study a Category A (experimental) or Category B (nonexperimental/investigational) classification, and that classification — not the trial phase — decides whether Medicare will ever cover the device itself, not just routine care costs.
Advance Beneficiary Notice (ABN) in Clinical Trial Billing: When Medicare Won’t Cover Routine Costs
How the ABN (CMS-R-131) works inside clinical trial billing: when it legitimately applies to a routine-cost item, why it cannot be used for sponsor-owed research costs, the GA/GZ/GX/GY modifiers, and how to build ABN triggers into a coverage analysis.
Cayuse Research Suite: IRB, Grants, and Compliance Software Overview
A module-by-module overview of the Cayuse Research Suite: IRB (Human Ethics), pre-award and post-award grants modules, COI/IACUC/biosafety compliance tools, vivarium management, and technology transfer, sourced directly from cayuse.com.
OnCore CTMS Coverage Analysis: How S/R/Q Billing Designations Actually Get Set
How the S (standard of care), R (research), and Q (qualifying) billing designations get derived from Medicare coverage analysis and applied inside a CTMS billing grid built on the OnCore model.
OIG Exclusion List Screening for Clinical Research Staff and Investigators
Why sponsors, sites, and IRBs must screen principal investigators, sub-investigators, coordinators, and other trial staff against the HHS-OIG LEIE — what exclusion means, who counts as research staff, how often to check, and what to do if you get a match.
NCI’s Cancer Trials Support Unit (CTSU): How It Centralizes Billing and Regulatory Support
CTSU is the NCI service that centralizes regulatory documentation, IRB/CIRB reliance, and billing-compliance support for sites running NCTN, NCORP, and ETCTN cancer trials.
Clinical Trial Billing Compliance: A Beginner’s Checklist
A practical, step-by-step checklist introducing clinical trial billing compliance for newcomers: Medicare Coverage Analysis, the routine-cost vs. research-cost split under NCD 310.1, the billing grid, and the errors that create False Claims Act exposure.
Human Subjects Research: Definition Under 45 CFR 46.102
The Common Rule’s two-part regulatory test for human subjects research: the ‘research’ definition at 45 CFR 46.102(l) and the ‘human subject’ definition at 46.102(e), including intervention, interaction, and identifiable private information.
Clinical Trial Budget Negotiation: Strategy for Sites and Sponsors
How research sites, sponsors, and CROs negotiate clinical trial budgets: per-patient cost benchmarking, non-refundable startup costs, screen-failure cost coverage, and payment milestone structuring.
Clinical Trial Study Renewal, Closure, and Reopening Determinations
How IRB continuing review renews a study’s approval, what a formal closure determination requires (final report, record retention), and what reopening a closed study actually involves.
Clinical Trial Budget Example: A Line-Item Walkthrough
A worked, illustrative composite clinical trial budget showing how startup costs, per-patient/per-visit costs, and institutional overhead combine into a site budget.
Clinical Trial Patient Retention: Strategies, IRB Review, and Diversity in Completion
A guide to clinical trial patient retention as an operational and IRB-compliance topic: retention vs. recruitment, why attrition matters for power and data integrity, IRB review of retention communications and payments, withdrawal rights, LTFU tracking, and how differential attrition can erode enrollment diversity gains.
Medicare Coverage Analysis for Clinical Trials: The Complete Process
A step-by-step guide to Medicare Coverage Analysis (MCA): the billing-compliance process, required before trial activation, that maps every protocol item to Medicare, the sponsor, or the patient under CMS NCD 310.1.
Third-Party Person-Locating Services for Long-Term Follow-Up (LTFU) Data Collection
How and when clinical research teams use commercial person-locating services to maintain contact with participants during long-term follow-up (LTFU), including the IRB, informed-consent, and HIPAA considerations raised by FDA’s long-duration gene therapy LTFU expectations.
IRB Noncompliance & Unanticipated Problem Reporting: What Must Be Reported, By Whom, and On What Timeline
A practical breakdown of what US federal regulations actually require an IRB to report — unanticipated problems, serious or continuing noncompliance, and suspension/termination of approval — to institutional officials, OHRP, and FDA, and on what timeline.
False Claims Act Liability in Clinical Trial Billing
How the False Claims Act applies to clinical trial billing, distinct from grant-related FCA exposure: Medicare/sponsor double-billing, NCD 310.1 coverage analysis, real DOJ settlements, qui tam mechanics, and the Stark Law/Anti-Kickback Statute intersection.
Pharmaceutical CRO Industry: A Sector Overview
A sector-level overview of the pharmaceutical CRO industry: market structure and tiers, why sponsors outsource, typical service lines, and how sponsors select and govern a CRO relationship.
Medicare Coverage Determinations: NCD vs LCD Explained
National vs Local Coverage Determinations explained: who issues NCDs and LCDs, how NCD 310.1 governs Medicare coverage of routine clinical trial costs, and how the mechanism drives clinical trial billing compliance.
Clinical Trial Site Selection: How Sponsors and CROs Choose Sites
How sponsors and CROs identify, evaluate, and select clinical trial sites: feasibility questionnaires, prior enrollment performance, patient population access, PI experience, infrastructure, and competing-trial considerations.
Patient Engagement in Clinical Trials: What It Means and How It Works
How patient engagement shapes clinical trial design and conduct, the mechanisms behind it (patient advisory boards, PCORI’s Engagement Rubric, PRO input), and how it differs from a Community Advisory Board or an FDA Diversity Action Plan.
The Evolution of Clinical Trials: From Nuremberg to Decentralized Trials
How clinical trial ethics and methodology evolved from the Nuremberg Code through the Declaration of Helsinki, the Belmont Report, ICH GCP, and modern risk-based and decentralized trials — and why the lineage matters for research administrators today.
Clinical Trial Outsourcing: In-House vs. Full-Service CRO vs. FSP — A Sponsor’s Decision Framework
A sponsor-side decision framework for clinical trial outsourcing: in-house/hybrid management vs. full-service CRO vs. Functional Service Provider (FSP), and the cost, control, speed, and capability tradeoffs that drive the choice.
Study Start-Up in Clinical Trials: From Site Selection to First Patient In
Study start-up is the phase between protocol finalization and first patient enrolled: site selection, contract and budget negotiation, IRB/ethics approval, document collection, and the Site Initiation Visit. What it covers, typical timelines, and where it commonly stalls.
Clinical Trial Recruitment Companies: Vendor Types, Services, and How to Evaluate One
A guide to the clinical trial patient-recruitment vendor landscape — SMOs, creative agencies, screening-technology platforms, and EHR-matching companies — and the criteria sponsors and sites use to evaluate and select one.
Clinical Trial Feasibility Assessment: How Sponsors Decide a Protocol Can Be Run
What clinical trial feasibility assessment evaluates before site selection: eligible patient population, protocol complexity, standard-of-care alignment, competing trials, and regulatory pathway.
Durham-Humphrey Amendment of 1951: How the FDA Created the Prescription vs. OTC Drug Distinction
The 1951 Durham-Humphrey Amendment split U.S. drug law into prescription (legend) and OTC categories and is still the statutory basis for that distinction today.
Clinical Trial Patient Recruitment: Methods, Screening, and Enrollment
A practical guide to clinical trial patient recruitment: referral, registry, community, and digital recruitment channels, the IRB-approval requirement for advertising materials, screening and informed consent, screen-failure tracking, NIH diversity/inclusion requirements, and how recruitment shapes trial timeline and budget.
The Cost of Running a Clinical Trial: A Budgeting Guide for Research Administrators
A research-administration guide to budgeting a clinical trial: the cost categories to plan for (site fees, IRB fees, CTMS, monitoring, CRO fees, participant payments, indirect costs), why costs vary so much by phase and therapeutic area, and what published studies (Sertkaya/ASPE, Moore et al./JAMA, DiMasi et al./Tufts) actually report.
What Is a Clinical Trial? The NIH Definition Explained
NIH defines a clinical trial by a four-question test, not by phase or product type. What the test asks, what it triggers (registration, GCP training, sIRB), how it differs from FDA’s and ICMJE’s definitions, and the 2026 BESH reclassification.
